kadmon corporation originally kadmon pharmaceuticals biopharmaceutical company based new york city also operations warrendale pa brighton company founded samuel founder former ceo imclone systems fully merged eli lilly company waksal served federal prison sentence stemming fiduciary role ceo imclone stock trading case released barred serving officer publicly traded company kadmon privately september amid plans take company ipo harlan w waksal brother samuel waksal became president chief executive officer samuel waksal remained title chief innovation science early sam waksal left kadmon june company filed paperwork july companys stock began trading nyse symbol switched nasdaq october september sanofi announced would acquire company deal completed november stock deregistered became subsidiary sanofi kadmon ongoing clinical trials specific fibrotic neurodegenerative diseases tesevatinib treat autosomal dominant polycystic kidney disease pkd autosomal recessive waksals leadership imclone company engaged early stage research projects years filing first drug kadmon however immediately began acquiring drugs advanced either already marketed us later stages clinical acquired warrendale pabased company three rivers pharmaceuticals ribasphere topotecan also signed agreement ontario canadabased valeant pharmaceuticals hepatitis c drugs ribavirin taribavirin cancer drugs acquired exelixis inhibitor several protein kinases tesevatinib entered phase ii clinical trial certain indications nonsmall cell lung polycystic kidney inhibitor protein kinases may increase sensitivity cancer cells radiation acquisition atypical biotechnology company chinese herbal formula added kadmons portfolio phytoceuticas formula four botanical products long used treatment gastrointestinal distress preclinical studies shown enhance therapeutic activity several anticancer phase ii trial combination irinotecan metastatic colon company acquired rights brighton mabased nano terra pharmacomer technology research platform three drug candidates clinical compounds include inhibitor rho kinase possible potential fibrotic focal cerebral triglyceride transfer protein mtp inhibitor explored metabolic phosphodiesterase inhibitor class drug used treatment erectile rights salirasib ras antagonist development cancer acquired concordia pharmaceuticals fort lauderdale also acquired rights burlington mabased dyax corp matrix targeted monoclonal antibody intended inhibit tumor blood vessel formation kadmon produces several generic drugs approved food drug administration united states httpsenwikipediaorgwikikadmoncorporation